Skip to content

Depression: all studies

Page 624 of 1,035: studies 6,231 to 6,240 of 10,348, newest first. Back to the depression overview

Research

Out-Of-Virtual-Body Experiences: Virtual Disembodiment Effects on Time Perception in VR

Virtual Reality Software and Technology October 9, 2024 Fabian Unruh, Jean-Luc Lugrin, M. Latoschik

This paper presents a novel experiment investigating the relationship between virtual disembodiment and time perception in Virtual Reality (VR). Recent work demonstrated that the absence of a virtual body in a VR application changes the perception of time. However, the effects of simulating an out-of-body experience (OBE) in VR on time perception are still unclear. We designed an experiment...

Mental Health Facilities With Ketamine Infusion Therapy in the United States in 2020: Co-Location of Dual Diagnosis Mental Health and Substance Use Disorder Treatment

Carolina Digital Repository October 9, 2024 Orrin D. Ware

Ketamine is an anesthetic that has been identified as an effective therapy for depressive disorders and related symptoms. Some studies have identified ketamine as having the potential to reduce substance use among individuals with a substance use disorder (SUD)-alongside psychotherapy. Further, SUDs often co-occur with depressive disorders. Using the National Mental Health Services Survey 2020,...

DOI: 10.17615/rd8y-nq91 (opens in new tab) Ketamine Mental health Dual diagnosis Dual grammatical number +1

Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer

Nature Mental Health October 7, 2024 Petros Petridis, Jack Grinband, Gabrielle Agin-Liebes et al. 10 citations

Psilocybin-assisted psychotherapy (PAP) has shown promise in treating mood and anxiety disorders in patients with cancer. However, patients with cancer often suffer from more than just depression and anxiety, and so far, PAP's effect on other psychiatric symptoms remains largely unknown. To address this gap, we pooled previously unpublished data from two phase II, randomized, placebo-controlled...

Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Health Disorders: A Scoping Review Protocol

October 7, 2024 Jennifer Pincombe, M.l. Williams, Sean Carruthers et al. 1 citation preprint

IntroductionThere has been a surge in research into psilocybin-assisted psychotherapy over the past decade, with many studies indicating this may be an effective novel intervention for several mental health disorders. Researchers are increasingly incorporating qualitative analysis into their studies in recognition of the rich, contextual information this provides. This scoping review aims to...

DOI: 10.31234/osf.io/ga9p2 (opens in new tab) Psilocybin Psychotherapist Mental health Protocol science +5

VR-Based Mantra Meditation for Mental Wellness

IEEE International Conference on Systems, Man and Cybernetics October 6, 2024 Ankita Garg, Ajoy Kumar, Shubham Garg et al.

Emotional stability, awareness, and attention may likely be enhanced by meditation and related techniques. Since meditation practitioners may need focus and engagement, virtual reality (VR) may be helpful. Even though there has been some research on the usefulness of VR for meditation, very few studies have looked at the effectiveness of VR on audible mantra repetition (AuMR). Our research...

VRZM: Exploring the Effect of Zen Meditation on EEG Patterns in Immersive Environments

IEEE International Conference on Systems, Man and Cybernetics October 6, 2024 Ajoy Kumar, Sahil Sankhyan, Kirti Tripathi et al.

There is growing interest in developing virtual reality (VR) applications for mental health therapies. However, the investigation of the effectiveness of meditation in VR environments for mental health issues like stress remains mostly unexplored. This study seeks to fill this knowledge gap by investigating the influence of VR-guided Zen meditation (VRZM) on stress levels. 40 individuals were...

Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome.

npj Mental Health Research October 6, 2024 Jack D. C. Dahan, David Dadiomov, Tijmen Bostoen et al. 13 citations

There is some evidence that the subjective effects of ketamine and other psychedelics like psilocybin are crucial for their therapeutic outcomes, such as treatment of depression or substance use disorder (SUD). We performed a meta-analysis and systematic review on the correlation of subjective symptoms and dissociation versus ketamine-induced therapeutic outcomes in patients with depression or...

DOI: 10.1038/s44184-024-00091-w (opens in new tab) Full text (opens in new tab) Psychedelic therapy Therapeutic efficacy Mental health treatment Ketamine research +1

UTILIZAÇÃO DE PSICODÉLICOS NO TRANSTORNO DEPRESSIVO REFRATÁRIO: UMA REVISÃO DE LITERATURA

Revista CPAQV - Centro de Pesquisas Avançadas em Qualidade de Vida October 4, 2024 Claudio Mateus Gnoatto, Keyla Liana Bezerra Machado, Rian Ricardo Henrique da Silva et al.

Introdução: O Transtorno Depressivo Maior (TDM) é altamente prevalente e incapacitante, ocupando um alto ônus globalmente. No Brasil, afeta 15,5% da população. A fisiopatologia da depressão envolve teorias, incluindo a monoaminérgica e a dos receptores monoaminérgicos, embora nenhuma seja conclusiva. Tratamentos farmacológicos baseiam-se na teoria monoaminérgica, apesar de suas limitações. Além...

Exploring the biocatalysis of psilocybin and other tryptamines: Enzymatic pathways, synthetic strategies, and industrial implications

Biotechnology Progress October 4, 2024 Lucas Henrique Junges, Marcelo Müller‐santos 5 citations

Abstract Tryptamines play diverse roles as neurotransmitters and psychoactive compounds found in various organisms. Psilocybin, a notable tryptamine, has garnered attention for its therapeutic potential in treating mental health disorders like depression and anxiety. Despite its promising applications, current extraction methods for psilocybin are labor‐intensive and economically limiting. We...

Rapid and Prolonged Antidepressant and Antianxiety Effects of Psychedelics and 3,4-Methylenedioxy-methamphetamine—A Systematic Review and Meta-Analysis

Psychoactives October 4, 2024 Dimy Fluyau, Vasanth Kattalai Kailasam, Neelambika Revadigar 2 citations

Background: There is ongoing research into the potential use of psychedelics and 3,4-methylenedioxy-methamphetamine (MDMA) as alternatives to commonly used medications for treating major depressive and anxiety disorders. Aims: We aimed to assess the efficacy of psychedelics and MDMA in managing depressive and anxiety symptoms and evaluate their safety profiles. Methods: We searched five...

DOI: 10.3390/psychoactives3040029 (opens in new tab) Meta-analysis Antidepressant Methylenedioxy Methamphetamine +1